Skip to content

The Efficacy and Safefy of the Innovative Operations and Tissue-engineering Flaps for Uretheral Stricture: An Ambispective cohort study

The Efficacy and Safefy of the Innovative Operations and Tissue-engineering Flaps for Uretheral Stricture: An Ambispective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076986
Enrollment
Unknown
Registered
2023-10-26
Start date
2023-10-31
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urethral stricture

Interventions

Tissue-engineering Repair Group:NA

Sponsors

Peking University First Hospital, Department of Urology
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Male patients over 18 years of age who underwent surgical treatment for urethral stricture at our center, including endoluminal surgery (urethral dilatation, balloon dilatation, DVIU, etc) and open surgery (urethral reconstruction, urethroplasty, etc.). (2) Have the ability to be independent, agree to the trial protocol after being informed of it, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients who fail to receive surgical treatment according to the original plan after being admitted to the hospital for physical reasons, serious infections, etc. (2) Those whose pathological diagnosis is accompanied by malignant neoplastic diseases such as urothelial carcinoma, or those who are accompanied by serious physical and mental diseases, organic diseases, etc., and whose life expectancy after surgery may be shorter than 3 years. (3) Samples not preserved as required.

Design outcomes

Primary

MeasureTime frame
Stricture recurrence rate, SRR;Secondary surgery incidence, SSI;Interval between second and subsequent surgeries;

Secondary

MeasureTime frame
Incidence of perioperative complications in patients;QoL;IPSS score;Improvement in urinary flow rate;

Countries

China

Contacts

Public ContactJian Lin

Peking University First Hospital, Department of Urology

linjianbj@163.com+86 138 0135 8465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026